Beam Therapeutics Inc. (BEAM)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| License and collaboration revenue | 8,466 | 7,470 | 14,269 | |
| Research and development | 101,758 | 98,816 | 94,258 | |
| General and administrative | 26,859 | 27,940 | 26,515 | |
| Total operating expenses | 128,617 | 126,756 | 120,773 | |
| Loss from operations | -120,151 | -119,286 | -106,504 | |
| Amount of increase (decrease) in the fair value of contingent consideration recognized in the income statement | - | - | 27 | |
| Change in fair value of non-controlling equity investments | 4,415 | -2,081 | -2,064 | |
| Change in fair value of derivative liabilities | 1,147 | 2,260 | -200 | |
| Change in fair value of contingent consideration liabilities | 28 | 27 | - | |
| Interest and other income (expense), net | 12,326 | 9,864 | 12,127 | |
| Total other income (expense) | 17,860 | 10,016 | 9,836 | |
| Net loss before income taxes | -102,291 | - | -96,668 | |
| Net loss | -102,291 | -109,270 | -96,668 | |
| Unrealized gain (loss) on marketable securities | -150 | -519 | 2,869 | |
| Comprehensive loss | -102,441 | -109,789 | -93,799 | |
| Net loss per common share , basic | -1 | -1.24 | -1.17 | |
| Net loss per common share , diluted | -1 | -1.24 | -1.17 | |
| Weighted average common shares outstanding, basic | 101,995,184 | 87,975,311 | 82,410,095 | |
| Weighted average common shares outstanding, diluted | 101,995,184 | 87,975,311 | 82,410,095 | |